Delaware
|
|
91-1835664
|
(State or other jurisdiction of
|
|
(I.R.S. Employer
|
incorporation or organization)
|
|
Identification Number)
|
|
Large accelerated filer [ ]
|
Accelerated filer [ ]
|
|
|
|
|
Non-accelerated filer [X]
|
Smaller reporting company [X]
|
|
|
|
|
|
Emerging growth company [ ]
|
Page
|
|
About This Prospectus
|
1
|
Where You Can Obtain More Information
|
1
|
Incorporation of Certain Information by Reference
|
2
|
Risk Factors
|
3
|
Special Cautionary Note Regarding Forward-Looking Statements
|
3
|
Prospectus Summary
|
4
|
Use of Proceeds
|
6
|
Selling Securityholders
|
6
|
Plan of Distribution
|
8
|
Legal Matters
|
10
|
Experts
|
10
|
|
●
|
Our Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC on March 30, 2022;
|
|
|
|
|
●
|
Our Quarterly Report on Form 10-Q for the quarter ended March 31, 2022, filed with the SEC on May 16, 2022; and
|
|
|
|
|
●
|
the description of our common stock contained in our registration statement on Form 8-A filed with the SEC on November 4, 2021 (File No. 001-37603), and any amendment
or report filed with the SEC for the purpose of updating the description.
|
|
●
|
statements relating to projected growth and management’s long-term performance goals;
|
|
●
|
statements relating to the anticipated effects on results of operations or our financial condition
from expected developments or events;
|
|
●
|
statements relating to our business and growth strategies; and
|
|
●
|
any other statements which are not historical facts.
|
|
●
|
our current and anticipated cash needs and our need for additional financing;
|
|
●
|
federal, state and foreign regulatory requirements;
|
|
●
|
our ability to conduct clinical trials with respect to our products and services;
|
|
●
|
our ability to develop and commercialize our products and services;
|
|
●
|
our ability to enter into agreements to implement our business strategy;
|
|
●
|
the acceptance of our products and services by patients and the medical community;
|
|
●
|
our ability to secure necessary media and reagents, as well as devices, materials and systems,
for our clinical trials and commercial production;
|
|
●
|
our manufacturing capabilities to produce our products;
|
|
●
|
our ability to obtain brown adipose (fat) tissue in connection with our ThermoStem Program;
|
|
●
|
our ability to maintain exclusive rights with respect to our licensed disc/spine technology;
|
|
●
|
our ability to protect our intellectual property;
|
|
●
|
our ability to obtain and maintain an adequate level of product liability insurance;
|
|
●
|
our ability to obtain third party reimbursement for our products and services from private and
governmental insurers;
|
|
●
|
the effects of competition in our market areas;
|
|
●
|
our reliance on certain key personnel;
|
|
●
|
further sales or other dilution of our equity, which may adversely affect the market price of our
common stock; and
|
|
●
|
other factors and risks referred to under “Risk Factors” on page 3 of this prospectus.
|
•
|
Disc/Spine Program (brtxDisc). Our lead
cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person’s own) cultured mesenchymal stem cells, or MSCs, collected from
the patient’s bone marrow. We intend that the product will be used for the non-surgical treatment of painful lumbosacral disc disorders or as a complimentary therapeutic to a surgical procedure. The BRTX-100 production process involves collecting bone marrow and whole blood from a patient, isolating and culturing (in a proprietary method) stem cells from the bone marrow and
cryopreserving the cells in an autologous carrier. In an outpatient procedure, BRTX-100 is to be injected by a physician into the patient’s painful
disc. The treatment is intended for patients whose pain has not been alleviated by non-surgical procedures or conservative therapies and who potentially face the prospect of highly invasive surgical procedures. We have obtained
authorization from the FDA to commence a Phase 2 clinical trial investigating the use of BRTX-100 in the treatment of chronic lower back pain arising
from degenerative disc disease and have commenced such clinical trial.
|
•
|
Metabolic Program (ThermoStem). We are
developing a cell-based therapy candidate to target obesity and metabolic disorders using brown adipose (fat) derived stem cells, or BADSC, to generate brown adipose tissue, or BAT. We refer to this as our ThermoStem Program. BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. Initial preclinical research conducted by us
and others indicates that increased amounts of brown fat in animals may be responsible for additional caloric burning, as well as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may
have a reduced risk for obesity and diabetes.
|
Common Stock Outstanding
|
|
3,637,594 shares
|
|
|
|
Common Stock Offered by the
Selling Securityholders
|
|
1,856,938 shares
|
|
|
|
Terms of the Offering
|
|
The selling securityholders will determine when and how they will sell the shares of common stock offered by this prospectus, as described in "Plan of Distribution."
|
Use of Proceeds
|
|
We will receive no proceeds from the sale of the shares of common stock being offered by the selling securityholders by this prospectus.
|
|
|
|
Risk Factors
|
|
An investment in the shares offered by this prospectus involves a degree of risk and should be considered only by persons who can afford the loss of their entire
investment. See “Risk Factors” on page 3.
|
|
|
|
Nasdaq Capital Market Symbol
|
|
“BRTX”
|
Name of Selling
Stockholder
|
Number of
Shares of
Common Stock
Beneficially
Owned Prior to Offering
|
Number of
Shares of
Common Stock
Offered Hereby
|
Number of Shares of Common Stock
Beneficially Owned After Offering
|
Percentage
of
Class After
Offering(8)
|
||||||||||||
Auctus Fund, LLC
|
181,515
|
(1)
|
1,676,580
|
274,177
|
(1)
|
4.99
|
%
|
|||||||||
John Desmarais
|
111,040
|
(2)
|
52,392
|
58,648
|
1.07
|
%
|
||||||||||
John Coghlan
|
91,522
|
(3)
|
40,734
|
50,788
|
*
|
|||||||||||
Tuxis Trust
|
44,138
|
(4)
|
33,024
|
11,114
|
*
|
|||||||||||
Seth Newman
|
114,307
|
(5)
|
32,013
|
82,294
|
1.50
|
%
|
||||||||||
WLW 2004 Irrevocable Trust FBO
John Westerman
|
33,072
|
(6)
|
11,528
|
21,544
|
*
|
|||||||||||
Crossover Capital Fund I, LLC
|
44,717
|
(7)
|
10,667
|
34,050
|
*
|
*
|
Less than 1%
|
(1)
|
Auctus Fund, LLC, or Auctus, holds a warrant for the purchase of up to 1,676,580 shares of our common stock. In addition, Auctus owns 1,543,158 shares of our Series A
preferred stock which are convertible into an aggregate of 1,543,158 shares of our common stock. However, such warrant is not exercisable for the purchase of our common stock, and such Series A preferred stock is not convertible into shares
of our common stock, to the extent Auctus would beneficially own, after such exercise and/or conversion, more than 4.99% of our outstanding shares of common stock. The number of shares of common stock reflected in the table above as being
beneficially owned by Auctus equals 4.99% of our outstanding common stock as of May 16, 2022 (prior to the offering and after giving effect to the exercise of all of the Warrants held by the selling securityholders). We have been advised by
Auctus that, as of May 16, 2022, it actually owned 174,988 shares of common stock.
|
(2)
|
Includes 52,392 shares of common stock issuable upon exercise of the Warrants.
|
(3)
|
Includes 40,734 shares of common stock issuable upon exercise of the Warrants.
|
(4)
|
Includes 33,024 shares of common stock issuable upon exercise of the Warrants.
|
(5)
|
Includes 32,013 shares of common stock issuable upon exercise of the Warrants.
|
(6)
|
Includes 11,528 shares of common stock issuable upon exercise of the Warrants. Also includes 5,003 shares of common stock owned by John Westerman, the beneficiary of
the trust, and 5,000 shares of common stock issuable upon the exercise of warrants held by Mr. Westerman.
|
(7)
|
Includes 10,667 shares of common stock issuable upon exercise of the Warrants.
|
(8)
|
Percentages assume the exercise of all of the Warrants for the purchase of an aggregate of 1,856,938 shares of common stock and that, following such exercises, the
number of shares of common stock outstanding will be 5,494,532.
|
•
|
underwritten offerings;
|
•
|
ordinary brokers transactions and transactions in which the broker solicits purchasers;
|
•
|
purchases by brokers or dealers as principal and resale by such purchasers for their own accounts pursuant to this prospectus;
|
•
|
block trades in which the broker-dealer so engaged will attempt to sell the shares as agent but may position and resell a portion of the block as principal to facilitate the
transaction;
|
•
|
to or through market makers or into an existing market for the common stock;
|
•
|
in other ways not involving market makers or established trading markets, including direct sales to purchasers or sales effected through agents;
|
•
|
through transactions in options, swaps or other derivatives, whether exchange listed or otherwise;
|
•
|
through the settlement of short sales;
|
•
|
in privately negotiated transactions; or
|
•
|
any combination of the foregoing, or by any other legally available means.
|
Item 14.
|
Other Expenses of Issuance and Distribution
|
SEC registration fee
|
|
$
|
671.34
|
|
Legal fees and expenses
|
|
10,000.00
|
||
Accounting fees and expenses
|
|
1,500.00
|
||
Miscellaneous fees and expenses
|
|
328.66
|
||
Total
|
|
$
|
12,500.00
|
Item 15.
|
Indemnification of Directors and Officers
|
Exhibit
Number |
|
Exhibit Description
|
|
|
|
4.1
|
|
Form of Registration Rights Agreement between BioRestorative Therapies, Inc. and the selling securityholders*
|
|
|
|
5.1
|
|
Opinion of Certilman Balin Adler & Hyman, LLP*
|
|
|
|
23.1
|
|
Independent Registered Public Accounting Firm’s Consent*
|
|
|
|
23.2
|
|
Consent of Certilman Balin Adler & Hyman, LLP (included in the opinion of Certilman Balin Adler & Hyman, LLP filed as Exhibit 5.1)*
|
|
|
|
24.1
|
|
Power of Attorney (included on signature page of the Registration Statement)
|
(i)
|
If the registrant is relying on Rule 430B:
|
(a)
|
Each prospectus filed by the registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the date the
filed prospectus was deemed part of and included in the registration statement; and
|
(b)
|
Each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on Rule
430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii), or (x) for the purpose of providing the information required by Section 10(a) of the Securities Act of 1933 shall be deemed to be part of and included in the
registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule 430B,
for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which
that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. Provided, however, that no statement made in a registration statement or prospectus that is part of the
registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale
prior to such effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date; or
|
(ii) |
If the registrant is subject to Rule 430C, each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements
relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness. Provided, however, that no statement
made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration
statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any
such document immediately prior to such date of first use.
|
|
BIORESTORATIVE THERAPIES, INC.
|
|
|
|
|
|
By:
|
/s/ Lance Alstodt
|
|
|
Lance Alstodt
|
|
|
President, Chief Executive Officer and Chairman of the Board
|
Signature
|
|
Title
|
|
Date
|
|
|
|
|
|
/s/Lance Alstodt
|
|
President, Chief Executive Officer and Chairman of the Board (Principal Executive Officer)
|
|
May 18, 2022
|
Lance Alstodt
|
|
|
||
|
|
|
|
|
/s/ Francisco Silva
|
|
Vice President, Research and Development, Secretary and Director
|
|
May 18, 2022
|
Francisco Silva
|
|
|
||
|
|
|
|
|
/s/ Robert E. Kristal
|
Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)
|
May 18, 2022
|
||
Robert E. Kristal
|
||||
/s/ Nickolay Kukekov
|
|
Director
|
|
May 18, 2022
|
Nickolay Kukekov
|
|
|
||
|
|
|
|
|
/s/ Patrick F. Williams
|
Director
|
May 18, 2022
|
||
Patrick F. Williams
|
||||
/s/ David Rosa
|
Director
|
May 18, 2022
|
||
David Rosa
|
|
|
Security
Type |
|
Security
Class
Title
|
|
Fee
Calculation or Carry Forward Rule |
|
Amount
Registered(1) |
|
Proposed
Maximum Offering Price Per Unit(2) |
|
Maximum
Aggregate Offering Price(2)
|
|
Fee
Rate
|
|
Amount of
Registration Fee |
Newly Registered Securities
|
||||||||||||||||
Fees to Be
Paid
|
|
Equity
|
|
Common Stock,
$.0001 par value,
registered for the
benefit of the
Selling Securityholders
|
457(c)
|
1,856,938
|
$3.90
|
$7,242,058
|
|
0.0000927
|
|
$671.34
|
||||
Fees Previously Paid
|
|
-
|
|
-
|
-
|
-
|
-
|
-
|
|
—
|
|
-
|
||||
Carry Forward Securities
|
||||||||||||||||
Carry
Forward
Securities
|
|
|
|
|
|
|
|
|
|
|||||||
|
|
Total Offering Amounts
|
|
|
$7,242,058
|
$671.34
|
||||||||||
|
|
Total Fees Previously Paid
|
|
|
||||||||||||
|
|
Total Fee Offsets
|
|
|
||||||||||||
|
|
Net Fee Due
|
|
|
|
(1)
|
Pursuant to Rule 416 under the Securities Act of 1933, as amended, this registration statement also covers an indeterminate amount of additional securities of BioRestorative Therapies, Inc. as may be issuable as a result of stock splits,
stock dividends or similar transactions.
|
(2)
|
Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(c) under the Securities Act of 1933, as amended, based on the average of the high and low sale prices for
our common stock as reported by the NASDAQ Capital Market on May 11, 2022.
|